Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Jan;93(1):223–229. doi: 10.1172/JCI116949

Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia.

D S Ng 1, L A Leiter 1, C Vezina 1, P W Connelly 1, R A Hegele 1
PMCID: PMC293756  PMID: 8282791

Abstract

We report a Canadian kindred with a novel mutation in the apolipoprotein (apo) A-I gene causing analphalipoproteinemia. The 34-yr-old proband, product of a consanguineous marriage, had bilateral retinopathy, bilateral cataracts, spinocerebellar ataxia, and tendon xanthomata. High density lipoprotein cholesterol (HDL-C) was < 0.1 mM and apoA-I was undetectable. Genomic DNA sequencing of the proband's apoA-I gene identified a nonsense mutation at codon [-2], which we designate as Q[-2]X. This mutation causes a loss of endonuclease digestion sites for both BbvI and Fnu4HI. Genotyping identified four additional homozygotes, four heterozygotes, and two unaffected subjects among the first-degree relatives. Q[-2]X homozygosity causes a selective failure to produce any portion of mature apoA-I, resulting in very low plasma level of HDL. Heterozygosity results in approximately half-normal apoA-I and HDL. Gradient gel electrophoresis and differential electroimmunodiffusion assay revealed that the HDL particles of the homozygotes had peak Stokes diameter of 7.9 nm and contained apoA-II without apoA-I (Lp-AII). Heterozygotes had an additional fraction of HDL3-like particles. Two of the proband's affected sisters had documented premature coronary heart disease. This kindred, the third reported apoA-I gene mutation causing isolated complete apoA-I deficiency, appears to be at significantly increased risk for atherosclerosis.

Full text

PDF
223

Images in this article

226Image
on p.226
226Image
on p.226

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbaras R., Puchois P., Fruchart J. C., Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun. 1987 Jan 15;142(1):63–69. doi: 10.1016/0006-291x(87)90451-7. [DOI] [PubMed] [Google Scholar]
  2. Bekaert E. D., Alaupovic P., Knight-Gibson C. S., Laux M. J., Pelachyk J. M., Norum R. A. Characterization of apoA- and apoB-containing lipoprotein particles in a variant of familial apoA-I deficiency with planar xanthoma: the metabolic significance of LP-A-II particles. J Lipid Res. 1991 Oct;32(10):1587–1599. [PubMed] [Google Scholar]
  3. Brunner D., Weisbort J., Meshulam N., Schwartz S., Gross J., Saltz-Rennert H., Altman S., Loebl K. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol. 1987 Jun 1;59(15):1271–1276. doi: 10.1016/0002-9149(87)90903-9. [DOI] [PubMed] [Google Scholar]
  4. Bury J., Rosseneu M. Quantification of human serum apolipoprotein AI by enzyme immunoassay. Clin Chem. 1985 Feb;31(2):247–251. [PubMed] [Google Scholar]
  5. Cheung M. C., Albers J. J. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984 Oct 10;259(19):12201–12209. [PubMed] [Google Scholar]
  6. Cheung M. C., Mendez A. J., Wolf A. C., Knopp R. H. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest. 1993 Feb;91(2):522–529. doi: 10.1172/JCI116231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Connelly P. W., Maguire G. F., Hofmann T., Little J. A. Structure of apolipoprotein C-IIToronto, a nonfunctional human apolipoprotein. Proc Natl Acad Sci U S A. 1987 Jan;84(1):270–273. doi: 10.1073/pnas.84.1.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Deeb S. S., Cheung M. C., Peng R. L., Wolf A. C., Stern R., Albers J. J., Knopp R. H. A mutation in the human apolipoprotein A-I gene. Dominant effect on the level and characteristics of plasma high density lipoproteins. J Biol Chem. 1991 Jul 25;266(21):13654–13660. [PubMed] [Google Scholar]
  9. Funke H., von Eckardstein A., Pritchard P. H., Albers J. J., Kastelein J. J., Droste C., Assmann G. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4855–4859. doi: 10.1073/pnas.88.11.4855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Funke H., von Eckardstein A., Pritchard P. H., Karas M., Albers J. J., Assmann G. A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest. 1991 Jan;87(1):371–376. doi: 10.1172/JCI114997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gjone E., Bergaust B. Corneal opacity in familial plasma cholesterol ester deficiency. Acta Ophthalmol (Copenh) 1969;47(1):222–227. doi: 10.1111/j.1755-3768.1969.tb05626.x. [DOI] [PubMed] [Google Scholar]
  12. Gordon D. J., Probstfield J. L., Garrison R. J., Neaton J. D., Castelli W. P., Knoke J. D., Jacobs D. R., Jr, Bangdiwala S., Tyroler H. A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989 Jan;79(1):8–15. doi: 10.1161/01.cir.79.1.8. [DOI] [PubMed] [Google Scholar]
  13. Gotoda T., Yamada N., Murase T., Sakuma M., Murayama N., Shimano H., Kozaki K., Albers J. J., Yazaki Y., Akanuma Y. Differential phenotypic expression by three mutant alleles in familial lecithin:cholesterol acyltransferase deficiency. Lancet. 1991 Sep 28;338(8770):778–781. doi: 10.1016/0140-6736(91)90665-c. [DOI] [PubMed] [Google Scholar]
  14. Gustafson A., McConathy W. J., Alaupovic P., Curry M. D., Persson B. Identification of lipoprotein families in a variant of human plasma apolipoprotein A deficiency. Scand J Clin Lab Invest. 1979 Jun;39(4):377–387. doi: 10.3109/00365517909106122. [DOI] [PubMed] [Google Scholar]
  15. Hegele R. A., Connelly P. W., Maguire G. F., Huff M. W., Leiter L., Wolfe B. M., Evans A. J., Little J. A. An apolipoprotein CII mutation, CIILys19----Thr' identified in patients with hyperlipidemia. Dis Markers. 1991 Mar-Apr;9(2):73–80. [PubMed] [Google Scholar]
  16. Hiasa Y., Maeda T., Mori H. Deficiency of apolipoproteins A-I and C-III and severe coronary heart disease. Clin Cardiol. 1986 Jul;9(7):349–352. doi: 10.1002/clc.4960090709. [DOI] [PubMed] [Google Scholar]
  17. Hixson J. E., Vernier D. T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990 Mar;31(3):545–548. [PubMed] [Google Scholar]
  18. Johnson W. J., Kilsdonk E. P., van Tol A., Phillips M. C., Rothblat G. H. Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LP-AI and LP-AI/AII. J Lipid Res. 1991 Dec;32(12):1993–2000. [PubMed] [Google Scholar]
  19. Johnson W. J., Mahlberg F. H., Rothblat G. H., Phillips M. C. Cholesterol transport between cells and high-density lipoproteins. Biochim Biophys Acta. 1991 Oct 1;1085(3):273–298. doi: 10.1016/0005-2760(91)90132-2. [DOI] [PubMed] [Google Scholar]
  20. Karathanasis S. K., Ferris E., Haddad I. A. DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7198–7202. doi: 10.1073/pnas.84.20.7198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Karathanasis S. K., Zannis V. I., Breslow J. L. Isolation and characterization of the human apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1983 Oct;80(20):6147–6151. doi: 10.1073/pnas.80.20.6147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Khoo J. C., Miller E., McLoughlin P., Steinberg D. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J Lipid Res. 1990 Apr;31(4):645–652. [PubMed] [Google Scholar]
  23. Klein H. G., Lohse P., Pritchard P. H., Bojanovski D., Schmidt H., Brewer H. B., Jr Two different allelic mutations in the lecithin-cholesterol acyltransferase gene associated with the fish eye syndrome. Lecithin-cholesterol acyltransferase (Thr123----Ile) and lecithin-cholesterol acyltransferase (Thr347----Met). J Clin Invest. 1992 Feb;89(2):499–506. doi: 10.1172/JCI115612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kuksis A., Myher J. J., Marai L., Geher K. Determination of plasma lipid profiles by automated gas chromatography and computerized data analysis. J Chromatogr Sci. 1975 Sep;13(9):423–430. doi: 10.1093/chromsci/13.9.423. [DOI] [PubMed] [Google Scholar]
  25. Kunitake S. T., Jarvis M. R., Hamilton R. L., Kane J. P. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6993–6997. doi: 10.1073/pnas.89.15.6993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Maeda E., Naka Y., Matozaki T., Sakuma M., Akanuma Y., Yoshino G., Kasuga M. Lecithin-cholesterol acyltransferase (LCAT) deficiency with a missense mutation in exon 6 of the LCAT gene. Biochem Biophys Res Commun. 1991 Jul 31;178(2):460–466. doi: 10.1016/0006-291x(91)90129-u. [DOI] [PubMed] [Google Scholar]
  27. Maguire G. F., Breckenridge W. C. Agarose gel electrophoresis of plasma lipoproteins using the Durrum cell. Clin Biochem. 1975 Jun;8(3):161–168. doi: 10.1016/s0009-9120(75)91675-6. [DOI] [PubMed] [Google Scholar]
  28. Maguire G. F., Lee M., Connelly P. W. Sodium dodecyl sulfate-glycerol polyacrylamide slab gel electrophoresis for the resolution of apolipoproteins. J Lipid Res. 1989 May;30(5):757–761. [PubMed] [Google Scholar]
  29. Manninen V., Tenkanen L., Koskinen P., Huttunen J. K., Mänttäri M., Heinonen O. P., Frick M. H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992 Jan;85(1):37–45. doi: 10.1161/01.cir.85.1.37. [DOI] [PubMed] [Google Scholar]
  30. Matsunaga T., Hiasa Y., Yanagi H., Maeda T., Hattori N., Yamakawa K., Yamanouchi Y., Tanaka I., Obara T., Hamaguchi H. Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2793–2797. doi: 10.1073/pnas.88.7.2793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Miller N. E. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987 Feb;113(2 Pt 2):589–597. doi: 10.1016/0002-8703(87)90638-7. [DOI] [PubMed] [Google Scholar]
  32. Nichols W. C., Gregg R. E., Brewer H. B., Jr, Benson M. D. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics. 1990 Oct;8(2):318–323. doi: 10.1016/0888-7543(90)90288-6. [DOI] [PubMed] [Google Scholar]
  33. Norum R. A., Lakier J. B., Goldstein S., Angel A., Goldberg R. B., Block W. D., Noffze D. K., Dolphin P. J., Edelglass J., Bogorad D. D. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med. 1982 Jun 24;306(25):1513–1519. doi: 10.1056/NEJM198206243062503. [DOI] [PubMed] [Google Scholar]
  34. Ordovas J. M., Cassidy D. K., Civeira F., Bisgaier C. L., Schaefer E. J. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem. 1989 Oct 5;264(28):16339–16342. [PubMed] [Google Scholar]
  35. Parthasarathy S., Barnett J., Fong L. G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990 May 22;1044(2):275–283. doi: 10.1016/0005-2760(90)90314-n. [DOI] [PubMed] [Google Scholar]
  36. Schaefer E. J., Ordovas J. M., Law S. W., Ghiselli G., Kashyap M. L., Srivastava L. S., Heaton W. H., Albers J. J., Connor W. E., Lindgren F. T. Familial apolipoprotein A-I and C-III deficiency, variant II. J Lipid Res. 1985 Sep;26(9):1089–1101. [PubMed] [Google Scholar]
  37. Schultz J. R., Gong E. L., McCall M. R., Nichols A. V., Clift S. M., Rubin E. M. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J Biol Chem. 1992 Oct 25;267(30):21630–21636. [PubMed] [Google Scholar]
  38. Shoulders C. C., Kornblihtt A. R., Munro B. S., Baralle F. E. Gene structure of human apolipoprotein A1. Nucleic Acids Res. 1983 May 11;11(9):2827–2837. doi: 10.1093/nar/11.9.2827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Stampfer M. J., Sacks F. M., Salvini S., Willett W. C., Hennekens C. H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991 Aug 8;325(6):373–381. doi: 10.1056/NEJM199108083250601. [DOI] [PubMed] [Google Scholar]
  40. Subbaiah P. V., Norum R. A., Bagdade J. D. Effect of apolipoprotein activators on the specificity of lecithin:cholesterol acyltransferase: determination of cholesteryl esters formed in A-I/C-III deficiency. J Lipid Res. 1991 Oct;32(10):1601–1609. [PubMed] [Google Scholar]
  41. Williamson R., Lee D., Hagaman J., Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7134–7138. doi: 10.1073/pnas.89.15.7134. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES